Relapsed or Refractory Mantle Cell Lymphoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Mantle cell lymphoma (MCL) is caused by the malignant transformation of a B lymphocyte on the rim of a lymph node follicle (the mantle zone). The transformed B lymphocyte grows uncontrollably, resulting in the accumulation of lymphoma cells, which causes the enlargement of lymph nodes. MCL cells can enter lymphatic channels and the blood, spreading to other lymph nodes or tissues like the bone marrow, liver, and gastrointestinal tract. In almost all cases, MCL is distinguished by the overexpression of cyclin D1 (a protein that promotes cell growth). Cyclin D1 overexpression is typically caused by a rearrangement (translocation) between chromosomes 11 and 14. Mantle cell lymphoma is associated with a relapsing and remitting course with the current treatment strategies, with a generally shorter duration of remission with each subsequent line of therapy. Recent drug approvals have improved outcomes for patients with relapsed MCL; in the United States, 5,970 new cases of MCL are being diagnosed in 2019, which is around 5 to 7% of all NHL cases.

 

The competitive landscape of Relapsed or Refractory Mantle Cell Lymphoma includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Relapsed or Refractory Mantle Cell Lymphoma across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory Mantle Cell Lymphoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Relapsed or Refractory Mantle Cell Lymphoma – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Carteyva®        JW Therapeutics           Phase 2

2          Fludarabine       Gilead Sciences            Phase 2

3          Zanubrutinib      BeiGene           Phase 2

4          Abemaciclib      Eli Lilly and Company    Phase 2

5          Ibrutinib AbbVie  Phase 2

6          Parsaclisib        Incyte Corporation         Phase 2

7          lenalidomide      Celgene Corporation     Phase 1

8          Gemin X           Gemin X           Phase 2

9          DTRMWXHS-12            Zhejiang DTRM Biopharma        Phase 1

10        Abemaciclib      Eli Lilly and Company    Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Familial Chylomicronemia Syndrome (FCS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder caused by mutations in the lipoprotein lipase gene, leading to hypertriglyceridemia and chylomicron accumulation in plasma. High triglycerides can result in complications like acute pancreatitis. FCS is also known as Lipoprotein lipase deficiency (LPLD), Type 1 hyperlipoproteinemia, and Endogenous hypertriglyceridemia. Diagnosis is based on fasting triglyceride levels exceeding 750 mg/dL and can be confirmed through genetic testing. Symptoms can emerge in infancy, childhood, or adolescence, with some patients remaining asymptomatic until adulthood. Common signs include Lipemia Retinalis (milky appearance in retinal veins), eruptive xanthomas (skin bumps with fatty deposits), abdominal pain, milky blood, and pancreatitis. Repeated pancreatitis is a severe complication that can lead to long-term pancreatic dysfunction and potential fatality if left untreated. FCS patients face a higher risk of pancreatiti...
Read more